Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Author:

Khoo Saye H,FitzGerald Richard,Saunders Geoffrey,Middleton Calley,Ahmad Shazaad,Edwards Christopher J,Hadjiyiannakis Dennis,Walker Lauren,Lyon Rebecca,Shaw Victoria,Mozgunov Pavel,Periselneris Jimstan,Woods Christie,Bullock Katie,Hale Colin,Reynolds Helen,Downs Nichola,Ewings Sean,Buadi Amanda,Cameron David,Edwards Thomas,Knox Emma,Donovan-Banfield I'ah,Greenhalf William,Chiong Justin,Lavelle-Langham Lara,Jacobs Michael,Northey Josh,Painter Wendy,Holman Wayne,Lalloo David G,Tetlow Michelle,Hiscox Julian A,Jaki Thomas,Fletcher Thomas,Griffiths Gareth,Paton Nicholas,Hayden Fred,Darbyshire Janet,Lucas Amy,Lorch Ulrika,Freedman Andrew,Knight Richard,Julious Stevan,Byrne Rachel,Cubas Atienzar Ana,Jones Jayne,Williams Chris,Song Anna,Dixon Jan,Alexandersson Anja,Hatchard Parys,Tilt Emma,Titman Andrew,Doce Carracedo Ale,Chandran Gorner Vatsi,Davies Andrea,Woodhouse Louis,Carlucci Nicola,Okenyi Emmanuel,Bula Marcin,Dodd Kate,Gibney Jennifer,Dry Lesley,Rashid Gardner Zalina,Sammour Amin,Cole Christine,Rowland Tim,Tsakiroglu Maria,Yip Vincent,Osanlou Rostam,Stewart Anna,Parker Ben,Turgut Tolga,Ahmed Afshan,Starkey Kay,Subin Sujamole,Stockdale Jennifer,Herring Lisa,Baker Jonathon,Oliver Abigail,Pacurar Mihaela,Owens Dan,Munro Alistair,Babbage Gavin,Faust Saul,Harvey Matthew,Pratt Danny,Nagra Deepak,Vyas Aashish

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference11 articles.

1. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase I, open-label, dose-escalating, randomized controlled study;Khoo;J Antimicrob Chemother,2021

2. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients;Jayk Bernal;N Engl J Med,2022

3. Kumarasamy N, Saha B, Jindal A, et al. Phase 3 trial of molnupiravir in adults with mild SARS-CoV-2 infection in India. Conference on Retroviruses and Opportunistic Infections; Feb 15, 2022 (abstract O-9).

4. Letter to the editor in response to Zhou et al;Troth;J Infect Dis,2021

5. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter;Griffiths;Trials,2021

Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3